Baohua Sun

The University of Texas MD Anderson Cancer Center

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

The University of Texas MD Anderson Cancer Center

Research Subjects

Research Interests

Baohua Sun has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

Edwin Roger Parra
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA
39 shared publications
Suyu Liu
Department of Biostatistics, The University of Texas MD Anderson Cancer Center , Houston, TX 77030
39 shared publications
Arjun Peddireddy
McGovern Medical School at UT Health, Houston, TX 77030, USA
22 shared publications
Armeen Mahvash
Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
22 shared publications
Cathy Eng
Division of Hematology & Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37235, USA
22 shared publications
Daniel M. Halperin
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
22 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Figure S3. Mutation prevalence in specified pathways for anal cancer (A);alterations noted in more commonly altered pathways (B).
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S3 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Figure S3. Mutation prevalence in specified pathways for anal cancer (A);alterations noted in more commonly altered pathways (B).
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Table S3. Univariable Cox regression models for Progression-free survival.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S3 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Table S3. Univariable Cox regression models for Progression-free survival.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Figure S4. Correlation of mRNA expression with copy number variation (A); genes associated with prolonged PFS and OS according to chromosome locus (B).
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S4 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Figure S4. Correlation of mRNA expression with copy number variation (A); genes associated with prolonged PFS and OS according to chromosome locus (B).
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Table S5. Adverse Events (All Grades).
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S5 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Table S5. Adverse Events (All Grades).
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Table S1. Clinical features and biopsy analysis according to clinical outcome with study treatment for each participant.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S1 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Table S1. Clinical features and biopsy analysis according to clinical outcome with study treatment for each participant.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Figure S5. Unsupervised clustering according to SBS type (A); Kaplan Meier curves for PFS (B) and OS (C) according to cluster; PFS according to SBS31 signature level (D).
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S5 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Figure S5. Unsupervised clustering according to SBS type (A); Kaplan Meier curves for PFS (B) and OS (C) according to cluster; PFS according to SBS31 signature level (D).
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Table S4. Univariable Cox regression models for Overall survival.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S4 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Table S4. Univariable Cox regression models for Overall survival.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Figure S2. Total counts of mutation types among all pretreatment anal cancers (A); TMB per patient (B); median PFS (C) and OS (D) according to TMB status.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S2 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Figure S2. Total counts of mutation types among all pretreatment anal cancers (A); TMB per patient (B); median PFS (C) and OS (D) according to TMB status.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Figure S1. Differentially expressed genes for according to PFS and OS (A), and immunologic genes with higher expression in association with prolonged PFS (B) and OS (C).
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S1 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Figure S1. Differentially expressed genes for according to PFS and OS (A), and immunologic genes with higher expression in association with prolonged PFS (B) and OS (C).
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Table S2. Study Representativeness Table.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S2 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
by Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, et al.
Supplementary Table S2. Study Representativeness Table.

Show all